Last updated: June 1, 2026
Lenvima (lenvatinib) is a targeted kinase inhibitor supplied through a multi-tier network: API manufacturing for lenvatinib and finished-dose drug product manufacturing for capsules. In the current commercial supply chain, the operational supplier set for Lenvima is dominated by branded-product supply contracts with established global CDMOs and API manufacturers that support oncology small-molecule production.
Who supplies LENVIMA (lenvatinib) drug substance and drug product?
Short answer: Lenvima’s supply chain splits between (1) lenvatinib active pharmaceutical ingredient (API) producers and (2) finished-dose capsule manufacturers that package and label product for US distribution.
Lenvatinib API supply chain: what supplier types are used
Featured roles typically include:
- API manufacturers producing lenvatinib (chemical synthesis, crystallization, drying, milling as needed).
- API testing and release labs (assay, impurities, residual solvents, particle size).
- Material handling suppliers for solvent recovery and specialized containment.
Lenvima drug product supply chain: what supplier types are used
Lenvima capsules require:
- Solid dosage CDMO capabilities (blending, granulation where applicable, capsule filling).
- Film coat or encapsulation lines if required for stability specs.
- Packaging suppliers (bottles, labels, cartons, desiccant systems).
- Quality systems that support US cGMP release.
Which companies are the contract manufacturers for LENVIMA capsules?
Short answer: Finished-dose Lenvima capsules are produced by contracted manufacturing sites (CDMOs and/or Eisai-controlled sites) with cGMP capabilities for oncology small molecules and packaging under traceable batch controls.
How to map capsule manufacturing suppliers in practice
Commercial “supplier” questions for Lenvima are answered operationally by:
- FDA facility listings tied to the drug product NDA/BLA (manufacturing and packaging sites).
- Batch-level release and distribution data reported through US commercial supply documentation.
- Company disclosures in CDMO announcements and regulatory submissions.
What are the key starting-material and raw-material supplier categories for lenvatinib?
Short answer: Lenvatinib production depends on suppliers of specialized intermediates, high-purity reagents, and controlled solvents used in multistep synthesis.
High-value supply categories
- Halogenated intermediates and substituted aromatic building blocks.
- Nitrogen and oxygen heterocycle precursors.
- Catalyst and ligand systems for key coupling steps.
- Solvents and crystallization media meeting residual solvent limits (ICH Q3C).
- Impurity-spec-critical reagents that require tight vendor qualification.
How many API suppliers support LENVIMA in the US?
Short answer: Lenvatinib supply is generally served by a primary API source with one or more qualified secondary suppliers to manage continuity of supply, subject to FDA comparability expectations and ICH process validation.
Why API redundancy matters for Lenvima
Targeted oncology molecules face:
- Multi-week synthesis schedules.
- Limited substitution flexibility for impurity profiles.
- Batch acceptance gatekeeping under fixed impurity specifications.
Which suppliers are linked to LENVIMA manufacturing sites in the FDA system?
Short answer: Lenvima manufacturing sites are defined in FDA listings for the drug product and API. Those listings identify the legal entities and physical sites that perform manufacture, packaging, labeling, and release.
Facility mapping approach used for supplier diligence
For each supplier inquiry, due diligence typically:
- Extracts FDA-registered manufacturing/packaging sites for Lenvima.
- Associates site addresses with the operating entity.
- Confirms whether the site is for API vs finished dosage vs packaging.
What suppliers matter most for LENVIMA supply continuity and shortage risk?
Short answer: The most supply-critical nodes are the API bottlenecks: key intermediates and the step(s) that constrain throughput or impurity control.
Operational risk points
- Step-limited reactor capacity for the core scaffold.
- Bottlenecks in isolation and crystallization yield.
- Specialty reagent availability for impurity-controlled steps.
- Solvent supply tied to regulatory residual limits.
How does LENVIMA supplier structure compare with other oncology small molecules (e.g., VEGFR inhibitors)?
Short answer: The pattern matches peers: centralized branded oversight with multiple qualified cGMP manufacturing sites and API redundancy for continuity, but small molecules with tight impurity specs often rely on fewer fully interchangeable API sources.
Comparison dimensions
- Degree of API redundancy.
- Dose form complexity (capsule vs tablet vs liquid).
- Packaging supply diversification.
- Regulatory lock-in from prior comparability history.
Key Takeaways
- Lenvima’s supply chain is a two-layer structure: lenvatinib API manufacturing plus finished-dose capsule manufacturing and packaging.
- Supplier-critical constraints sit at the API intermediate and impurity-controlled synthesis steps, not packaging.
- Supplier diligence for Lenvima is best handled by mapping FDA-registered manufacturing and packaging sites for the drug product and API, then linking those sites to legal entities and known CDMO/APIs in the chain.
FAQs
-
How do I identify the FDA-registered manufacturers for LENVIMA capsules?
Use the FDA facility and drug product listings tied to the Lenvima NDA and extract the manufacturing, packaging, and labeling sites.
-
Are there multiple API sources for lenvatinib supporting LENVIMA?
Lenvatinib supply is commonly qualified with more than one source, with the exact set defined by regulatory listings and quality system approvals.
-
What supplier nodes create the highest shortage risk for lenvatinib?
The highest risk nodes are API synthesis bottlenecks and impurity-spec-critical steps, especially those tied to constrained intermediates or crystallization yield.
-
Do LENVIMA formulation or packaging suppliers change when the API source changes?
Packaging suppliers can remain stable while API changes trigger comparability and release testing; formulation changes are more tightly constrained.
-
How do I assess whether a CDMO can supply LENVIMA at commercial scale?
Evaluate whether the CDMO has cGMP history for small-molecule oncology APIs/capsules, can meet lenvatinib impurity specs, and can support validated scale and dissolution/stability requirements for capsules.
References
- FDA. Drugs@FDA: LENVIMA (lenvatinib) drug approval and labeling information. (Accessed 2026-06-01).
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for lenvatinib (LENVIMA). (Accessed 2026-06-01).
- FDA. Drugs@FDA and associated facility/labeling information for manufacturing and packaging sites. (Accessed 2026-06-01).
